Renibus Therapeutics® (“Renibus”), a clinical-stage biotech company focusing on the prevention and treatment of cardiorenal diseases, announced today that Frank Stonebanks has been appointed as Chief Executive Officer, bringing more than 25 years of experience across healthcare and venture capital (VC) to lead Renibus in its next phase of growth. The Company also announced it has completed a $15 million extension as part of of its Series A financing, led by family offices specializing in biotech investments, closing the round at $35 million.
Search
Recent Posts
See AllSpring has sprung across the U.S., and many of you are probably ready to hit the course and outdoor courts. But a recent injury may be interrupting your golf game or tennis match. If you’re hesitant o
TripleBlind, creator of the most complete and scalable solution for privacy enhancing computation, announced acceptance to present at IEEE’s 42nd International Conference on Distributed Computing Syst
The Mighty, the world's leading health community bringing the patient's voice to life across the healthcare industry, has hired Matthew Michelson, Ph.D. as President. Dr. Michelson is a pioneer in the
